Secukinumab (Cosentyx)
Dilution requiredFull monograph review pending
U.S. label preparation
Cosentyx · Dilution required
- Preparation
- Use the IV concentrate and 0.9% sodium chloride. Select a 50 or 100 mL bag from section 2.13, Table 1 using the indication, body weight and loading or maintenance regimen. Remove a volume equal to the prescribed concentrate before adding the drug.
- Administration and handling
- Gently mix and infuse over 30 minutes. Check the actual IV vial before preparation. The subcutaneous devices follow different instructions.
Product and source details
Novartis Pharmaceuticals Corporation · BLA761349
Product NDC: 0078-1168
SPL effective 2026-10-15 | SPL version 31. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.